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Abstract	  
	  Biomarkers	   are	   vital	   to	   detect	   diseases	   in	   various	   clinical	   stages.	   A	   variety	   of	  cancer	   serum	  biomarkers	   are	   already	   known,	  while	   for	  more	   accurate	   cancer-­‐type	   detection,	   there	   required	   more	   rigorous	   evaluation	   manners,	   especially	  computational	  evaluation	  measures,	  for	  biomarkers.	  In	  this	  review,	  we	  first	  show	  three	   typical	   pitfalls	   in	   finding	   biomarkers	   and	   their	   examples,	   after	   briefly	  presenting	  standard	  five	  clinical	  biomarker	  screening	  phases	  by	  National	  Cancer	  Institute.	   We	   then	   introduce	   current	   computational	   biomarker	   evaluation	  measures,	  including	  current,	  standard	  methods	  with	  their	  intrinsic	  features.	  We	  further	  show	  an	  up-­‐to-­‐date	  list	  of	  existing	  cancer	  serum	  biomarkers,	  pointing	  out	  several	   issues,	  being	  caused	  by	   the	   limitations	  of	  current	  biomarker	  evaluation	  approaches.	  Finally	  we	  discuss	  the	  current	  attempts	  to	  develop	  new,	  statistically	  robust,	   computational	   serum-­‐based	  biomarker	  measures	   in	   terms	  of	   specificity	  to	  each	  of	  various	  cancer	  types.	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1.	  Introduction	  	  Biomarkers	   are	   believed	   to	   increase	   the	   accuracy	   of	   diagnosis	   to	   precisely	  characterize	   the	  disease	   in	  a	  diagnostic	  or	  prognostic	   level.	  Biomarkers	  predict	  the	   response	  of	   the	  patient,	  helping	   to	  guide	  a	  more	   tailored	   treatment	   for	   the	  patient.	   Serum	   biomarkers	   are	   more	   appealing	   due	   to	   their	   simplicity	   of	  obtaining	  the	  blood	  samples.	  There	  are	  several	  serum	  cancer	  biomarkers,	  which	  are	   routinely	   used	   in	   clinical	   oncology,	   e.g.	   prostate	   specific	   antigen	   (PSA)	   for	  prostate	  cancer	  and	  cancer	  antigen	  (CA)-­‐125	  for	  ovarian	  cancer.	  However,	  their	  applications	   have	   significant	   limitations,	   because	   of	   low	   specificity,	   i.e.	   small	  probability	  of	  samples	  with	  no	  biomarkers	   in	  all	  non-­‐diseased	  samples.	   In	   fact,	  the	   issue	  of	   specificity	   has	  become	  much	  more	   acute,	   since	  more	   than	  30%	  or	  higher	   circulatory	   PSA	   level	   patients	   have	   to	   go	   for	   extensive	   testing	   and	  treatment,	   indicating	   its	   lack	   of	   specificity	   of	   prostate	   tumor	   detection	   [1].	   In	  summary,	   lack	   of	   specific	   serum	   biomarkers	   has	   impeded	   the	   change	   in	  morbidity	  and	  mortality	  in	  cancer	  patients.	  	  	  The	   traditional	   "a	   priori"	   approach	   for	   biomarker	   development	   needs	   a	   well-­‐established	  biological	  procedure,	  being	  subjected	  to	  two-­‐step	  clinical	  validation:	  1)	   simple	   test	   with	   a	   high	   level	   of	   quality	   control,	   and	   2)	   planned	   statistical	  prospective	   evaluations	   within	   the	   validation	   pilot	   studies	   to	   prove	   an	  established	   clinical	   impact	   [2].	   Contrarily,	   more	   recently	   "a	   posteriori"	  approaches	   evaluate	   the	   clinical	   rationale	   of	   a	   "biological	   indicator"	   through	   a	  systematic	  discovery	  of	  various	  screening	  tools	  (e.g.	  microarray,	  bioinformatics,	  High-­‐throughput	   DNA	   sequencing).	   These	   biological	   instruments	   are	   "black	  boxes",	  meaning	   that	   a	   clinical	  usage	   can	  be	  discovered	   through	   research	  pilot	  studies.	  Computational	  approaches	  give	  possible	  candidates	  for	  detecting	  certain	  diseases,	   by	   "sensitivity"	   and	   "specificity",	  within	   a	   patient	   population,	   but	   the	  proper	  quantification	  of	  a	  single	  biomarker	  in	  serum	  is	  limited	  to	  the	  evaluation	  technicalities.	  Therefore	   this	   review	  will	   focus	  on	   the	   latter	  approach	  since	   the	  recent	   technologies	   provide	   a	   plethora	   of	   potential	   candidates	   which	   are	   in	  proper	  need	  of	  evaluation.	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Over	   the	  past	   twenty	  years,	   biomarkers	  have	   shown	  significant	  promise	   in	   the	  mechanism	  of	  how	  it	  will	  transform	  a	  patient’s	  treatment.	  Therefore,	  biomarker	  research	   has	   been	   aimed	   towards	   the	   development	   of	   personalized	   targeted	  therapy.	  Despite	  the	  recent	  technological	  advancements,	  there	  are	  still	  relatively	  few	  biomarkers	  that	  are	  in	  routine	  clinical	  use	  today	  [3].	  With	  a	  growing	  number	  of	   complex	   genomic	   tests	   for	   biomarker	   signatures	   becoming	   commercially	  available,	  the	  promise	  of	  personalized	  medicine	  is	  fast	  becoming	  a	  reality.	  Much	  attention	  has	  to	  be	  placed	  on	  the	  reason	  why	  the	  promising	  biomarkers	  and	  the	  biomarkers	  signatures	  entering	  the	  clinic	  is	  a	  long	  road	  ahead	  [4].	  	  	  
2.	  Biomarker	  Discovery	  Validation:	  Three	  Pitfalls	  	  In	   this	   section,	   we	   first	   briefly	   show	   the	   most	   widely	   accepted	   guideline	   for	  evaluation	  and	  validation	  of	  biomarkers	  (Diagram	  1):	  “Early	  Detection	  Research	  Network	   (EDRN)”	  developed	  by	  National	   Cancer	   Institute	   [5].	  We	   then	   explain	  typical	   pitfalls	   and	   their	   examples	   of	   clinical	   biomarker	   evaluation	   failures,	  mainly	   caused	   by	   poor	   experimental	   design	   and	   inappropriate	   choice	   of	   the	  diagnostic	  assay.	  	  Phase	  I	  of	  EDRN	  is	  the	  discovery	  of	  biomarkers	  through	  knowledge–based	  gene	  selection,	  gene	  expression	  profiling	  or	  protein	  profiling	  by	  setting	  the	  platform	  to	  rank	   and	   select	   the	   biomarkers	   via	   their	   characteristics.	   Most	   biomarker	  candidates	  are	  obtained	  from	  organized	  and	  characterized	  cohort	  studies,	  tissue	  banks	   or	   clinical	   trials	   with	   active	   follow-­‐ups.	   Phase	   II	   establishes	   a	   clear	  indication	   of	   the	   biomarker’s	   intended	   use	   in	   clinic	   by	   checking	   the	   validity,	  portability	   and	   reproducibility	   of	   these	   biomarker	   assays	   in	   various	   samples	  amongst	   various	   laboratories	   and	   clinics.	   The	   sensitivity	   and	   the	   specificity	  determined	  during	   this	  stage,	  which	  assess	   the	  quality	  of	   the	  biomarker,	   in	   the	  designated	   assay	   for	   clinical	   usage.	   Phase	   III	   evaluates	   the	   sensitivity	   and	   the	  specificity	   of	   the	   biomarker	   in	   various	   other	   diseases,	   to	   see	   its	   potential	  predictive	   value	   to	   ascertain	   the	   disease	   occurrence.	   Phase	   IV	   assesses	   the	  sensitivity	   and	   the	   specificity	   on	   prospective	   cohorts	   [6],	   identifying	   the	   false	  negative	   samples	  by	   evaluating	   the	   extent	   and	   characteristics	   of	   the	  disease	   at	  the	  time	  of	  detection.	  This	  process	  estimates	  the	  false	  referral	  rate	  and	  evaluates	  the	  diagnostic	   features	  of	   the	  biomarker,	   e.g.	   the	  definition,	   stage,	   grade	  of	   the	  tumor	  types.	  Phase	  V	  evaluates	  the	  overall	  benefits	  and	  the	  risks	  of	  performing	  the	  new	  biomarker	  diagnostic	  test	  in	  a	  controlled	  screened	  population.	  	  In	   2011,	   there	   were	   7720	   publications	   on	   biomarkers	   usage,	   but	   only	   407	   of	  these	   were	   actually	   patented	   [7].	   Surprisingly,	   from	   these	   407	   patented	  biomarkers,	   none	   have	   obtained	   FDA	   approval.	   This	   fact	   reflects	   how	   many	  studies	  report	  the	  discovery	  of	  different	  potential	  biomarkers,	  but	  most	  of	  them	  do	  not	  meet	  the	  criteria	  of	  high	  sensitivity	  and	  specificity,	  necessary	  to	  enter	  into	  the	   clinical	   setting.	  Moreover,	   there	   is	   a	   shortage	   of	   quality	   specimens	   for	   the	  validation	   studies.	   This	   subsequently	   pushes	   the	   biomarker	   candidate	   into	  pitfalls	   preventing	   it	   from	   approval.	   In	   conclusion,	   the	   standardization	   of	  quantitation	  for	  the	  quality	  and	  the	  validation	  of	  the	  candidate	  biomarker	  need	  to	  be	  urgently	  improved	  to	  decrease	  the	  excessive	  economical	  resources	  placed	  on	  weak	  candidates.	  We	  here	  raise	  three	  typical	  pitfalls	  in	  biomarker	  validation	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and	  their	  examples:	  	  Pitfall	  1:	  incorrect	  false	  positive	  control	  A	  lack	  of	  external	  validation	  studies	  cannot	  justify	  the	  potential	  biomarker	  on	  its	  specified	  performance.	  For	  example,	   the	  broad	  sensitivity	  scale	   (0.40-­‐0.73)	  can	  be	  easily	  obtained	  under	  a	   fixed	  specificity	  of	  0.95,	  even	   though	   the	  specimens	  were	  not	  obtained	  at	  the	  time	  of	  diagnosis	  [8].	  	  Example:	  Management	  of	  prostate	   cancer	  has	   long	  employed	  biomarkers,	   from	  the	   stage	   of	   detection	   to	   treatment	   monitoring.	   In	   1987,	   serum	   PSA	   was	  suggested	   as	   a	   biomarker	   since	   its	   increased	   quantity	   as	   detected	   in	   prostate	  cancer	  can	  represent	  abnormalities	  in	  the	  architecture	  and	  the	  vasculature	  of	  the	  prostate	  [9].	  Thus,	  it	  was	  believed	  that	  PSA	  quantity	  was	  directly	  correlated	  with	  the	  advancing	  clinical	  stage	  of	  the	  cancer	  and	  is	  useful	  for	  monitoring	  of	  disease	  curative	   therapy.	  However,	  PSA-­‐based	  screening	   for	  prostate	  cancer	   is	  plagued	  by	  false	  positives	  [9],	  resulting	  in	  an	  only	  25-­‐40%	  positive	  predictive	  value	  (i.e.	  high	  probability	  of	  a	  diseased	  sample	  in	  all	  samples	  with	  a	  biomarker	  present).	  The	  major	  reason	  for	  such	  high	  false	  positive	  rates	  was	  derived	  from	  the	  fact	  that	  several	   non-­‐cancerous	   events	   may	   elevate	   the	   level	   of	   PSA.	   For	   instance,	  inflammation,	  infection,	  and	  trauma	  are	  more	  common	  causes	  of	  elevated	  serum	  PSA	  than	  cancer.	  	  Pitfall	  2:	  sample	  population	  size	  Inappropriate	   statistical	   results	  may	   result	   from	   the	   small	   number	   of	   patients	  and	   control	   subjects	   in	   published	   studies	   [8].	   The	   outcomes	   from	   the	   small	  sample	   size	   would	   reflect	   logical	   fallacies	   in	   candidate	   markers	   due	   to	   the	  deficiencies	   in	   the	   inadequate	   study	   design.	   Biomarker	   development	   is	   a	   team	  process	  [8].	  Since	  most	  tests	  and	  assays	  are	  outsourced,	  conceptual	  blind	  spots	  may	   arise	   which	   eventually	   result	   in	   unjustified	   conclusions.	   For	   serum	  biomarker	   studies,	   bodily	   fluids	   (blood,	   urine,	   semen,	   etc)	   and	   tissues	   are	  collected	  from	  a	  group	  of	  patients	  of	  different	  disease	  stages,	  and	  are	  compared	  with	   a	   group	   of	   healthy	   persons.	   Since	   sensitivity	   improves	   with	   increased	  disease	  stage,	  hence	  the	  lack	  of	  consistency	  through	  observational	  studies	  results	  in	  ‘contradicting	  published	  reports	  likely	  [resulted]	  from	  studies	  testing	  different	  patient	  populations,	  using	  different	  methodologies,	  and	  applying	  different	   [cut-­‐offs]	  for	  a	  positive	  test’	  [10].	  	  	  Example:	   Xu	   et	   al.	   reported	   that	   lysophosphatidic	   acid	   is	   a	   potential	   effective	  biomarker	   for	   ovarian	   carcinoma	   [11,	   12].	   In	   the	   Xu	   study,	   elevated	   levels	   of	  plasma	   lysophosphatidic	   acid	   were	   detected	   in	   90%	   of	   phase	   I	   patients	   and	  subsequently	   in	   100%	   of	   phases	   II,	   III,	   or	   IV	   patients.	   It	   was	   also	   detected	   in	  100%	   of	   recurrent	   ovarian	   cancer	   patients.	   Hence,	   it	   was	   demonstrated	   that	  Lysophosphatidic	  acid	  was	  a	  far	  more	  superior	  potential	  biomarker	  than	  CA-­‐125,	  which	   only	   had	   a	   reported	   sensitivity	   of	   22%	   and	   60%	   in	   their	   stage	   I	   and	  advanced	   patients,	   respectively.	   However,	   Baker	   independently	   validated	   the	  lysophosphatidic	   acid	   test	   for	   ovarian	   cancer	   and	   concluded	   that	  lysophosphatidic	   acid	   levels	   are	   indistinguishable	   from	   ovarian	   case	   patients	  from	  controls	  subjects	  [13].	  Hence,	  the	  Xu	  study	  was	  plagued	  by	  deficiencies	  that	  existed	   in	   the	  studied	  population.	   In	  other	  words,	   the	  small	   sample	  size	  of	  149	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patients	   demonstrated	   the	   "strawman	   argument"	   [8].	   In	   conclusion,	  lysophosphatidic	   acid	   was	   found	   to	   be	   a	   nonspecific	   marker	   that	   is	   highly	  affected	   by	   small	   changes	   in	   sample	   collection	   practices,	   as	  well	   as	   processing	  practices.	  	  Pitfall	  3:	  inadequate	  experimental	  results	  Choosing	   the	   optimal	   analysis	   method	   is	   critical	   in	   biomarker	   search	   by	  proteomics	   and	   metabolomics	   [14].	   Preparations	   of	   the	   sample	   for	   proteomic	  and	  metabolic	  analyses	  are	  very	   important	  and	  can	  prevent	  errors	   that	  always	  will	   affect	   the	   final	   results.	  Unfortunately,	  most	  published	   studies	  only	   analyze	  the	   sample	   once,	   which	   does	   not	   validate	   the	   reproducibility	   of	   the	   results.	  Studies	   should	   permit	   the	   deviation	   from	   the	   mean	   (i.e.	   the	   error	   in	   the	  measurement)	  to	  avoid	  the	  pitfall	  of	  sample	  biases	  [8,	  14-­‐16].	  	  	  Example:	   Leman	   et	   al.	   reported	   that	   early	   prostate	   cancer	   antigen-­‐2	   (EPCA-­‐2)	  was	  a	  novel	  putative	  prostate	  cancer	  biomarker	  that	  performed	  better	  than	  PSA	  for	  diagnosis,	  prognosis,	  and	  disease	  maintenance	  [17].	  	  The	  study	  comprised	  of	  385	  men,	   reported	  a	  92%	  specificity,	   for	  overall	  prostate	  cancer,	   in	  contrast	   to	  65%	  for	  PSA	  [6,	  8,	  12,	  17,	  18].	  After	  a	  thorough	  examination	  of	  the	  methods	  was	  performed,	   the	   assays	   show	   technical	   inadequacies	   and	   discrepancies.	  Diamandis	   reported	   that	   the	   Leman	   assay	   design	  would	   not	   be	   a	   "sensitive	   or	  specific	   measure"	   to	   measure	   EPCA-­‐2	   in	   serum	   [1,	   19].	   More	   specifically,	   the	  investigation	   shows	   flaws	   included	   reporting	   values	   that	   were	   beyond	   the	  detection	   limit	   of	   the	   assay	   and	   improper	   reagents	   used	   to	   “capture”	   EPCA-­‐2.	  Since	   the	   assay	  was	   technically	   inadequate,	   the	   study	   resulted	   in	  misleadingly	  "highly	   promising"	   from	   unreproducible	   data.	   This	   study	   typically	   addresses	   a	  failure	  phenomenon,	  where	  the	   inhibition	  of	   the	  assay	  verses	  direct	  changes	   in	  the	  analysis	  [8].	  	  	  Current	   biomarkers	   have	   been	   plagued	   by	   many	   pitfalls	   including	   the	   above	  three	  typical	  cases.	  In	  particular,	  the	  example	  in	  the	  first	  pitfall	  can	  be	  rephrased	  such	   that	  many	   protein	   biomarkers	   are	   not	   cancer	   specific;	   that	   is,	   conditions	  other	  than	  the	  disease	  itself,	  may	  cause	  a	  protein	  biomarker	  to	  be	  present	  or	  be	  at	  an	  elevated	   level.	   In	  addition,	   the	   levels	  of	   some	  protein	  biomarkers	  are	  not	  elevated	   in	   all	   patients	   with	   a	   particular	   cancer	   [18].	   Therefore,	   the	  computational	   assessment	   is	   an	   important	   tool	   to	   validate	   the	   quality	   of	   the	  biomarker.	  	  
3.	  Computational	  Measures	  for	  Evaluating	  Biomarkers	  	  Diagram	  2	   is	   a	   2	   x	   2	   contingency	   table,	   showing	   cross-­‐correlate	   disease	   status	  with	   biomarker	   presence.	   This	   table	   is	   obtained,	   under	   a	   pre-­‐determined	  threshold	   for	   the	   biomarker	   test,	   to	   examine	   the	   usefulness	   of	   the	   candidate	  biomarker	  in	  the	  diagnostic,	  prognostic,	  predictive	  appraisal	  of	  the	  disease.	  This	  table	  has	   four	   cells	  with	   samples	   labeled	  by	  True	  Positive	   (TP),	   False	  Negative	  (FN),	   False	   Positive	   (FP)	   and	   True	   Negative	   (TN),	   which	   are	   mainly	   used	   to	  compute	   the	  measures	   introduced	   below.	   Hereafter	  we	   use	   each	   of	   these	   four	  labels	  as	  the	  number	  of	  the	  corresponding	  samples.	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3.1	  Sensitivity	  and	  specificity	  	  Sensitivity	  or	  True	  Positive	  Rate	  (TPR)	  is	  the	  probability	  that	  the	  biomarker	  will	  be	   detected	   positive	   in	   the	   disease	   samples.	   In	   Diagram	   2,	  sensitivity=Probability(Biomarker	   present/Disease	   present),	   which	   can	   be	  estimated	  by	  (TP/(TP+FN)).	  Whereas,	  specificity,	  known	  as	  True	  Negative	  Rate	  (TNR),	  is	  the	  probability	  that	  the	  biomarker	  will	  be	  absent	  in	  a	  non-­‐diseased	  case	  and	   can	   be	   estimated	   by	   (TN/(FP+TN))	   [20].	   Both	   are	   scaled	   such	   that	   values	  close	   to	   1	   to	   indicate	   high	   accurate	   diagnostic	   value	   and	   a	   value	   of	   zero	   is	  equivalent	  undefined	  diagnostic	  value.	  The	  relationship	  between	  sensitivity	  and	  specificity	   can	   be	   complemented	   via	   1−specificity,	  which	   is	   False	   Positive	  Rate	  (FPR).	  	  A	  highly	  sensitive	  test	  will	  be	  positive	  in	  nearly	  all	  patients	  with	  the	  disease,	  but	  there	  may	  also	  be	  positive	   for	  many	  patients	  without	   the	  disease.	   Ideally,	  most	  patients	  without	  the	  disease	  should	  present	  negative	  test	  results.	  So	  specificity	  is	  defined	   to	   check	   the	   sensitivity	   over	   patients	   without	   the	   disease.	   The	   ideal	  biomarker	   to	   be	  used	   as	   a	   diagnostic,	   prognostic,	   predictive	   or	   pharmacogenic	  tool	   should	  be	  both	   sensitive	  and	  specific.	  Therefore,	   sensitivity	  and	  specificity	  combined	  assess	  the	  quality	  performance	  of	  the	  biomarker.	  One	  measure	  for	  this	  purpose	  is	  Youden	  index,	  defined	  as	  (sensitivity	  +	  specificity	  -­‐1)	  [20].	  	  
3.2	  Predictive	  values	  
	  Predictive	  values	  are	  conditional	  proportional	  measures	  of	  the	  total	  cohort	  with	  positive	   and	   negative	   index	   (Diagram	   2).	   In	   other	  words,	   a	   positive	   predictive	  value	   is	  probability	   that	   a	   case	  with	   a	  biomarker	  present	   is	  diseased	  and	  vise-­‐versa	   for	   the	  negative	  predictive	  value.	  The	  positive	  predictive	  value	  decreases	  proportionally	   with	   the	   prevalence	   of	   the	   disease,	   indicating	   the	   biomarker	  assessment	  being	  not	  reliable	   for	  rare	  conditions,	  which	  will	   result	   in	  many	  FP	  results,	  compared	  to	  the	  TP	  results.	  	  
3.3	  Likelihood	  ratios	  
	  The	   likelihood	   ratio	   is	   a	  diagnostic	   test	   to	  assess	  of	   the	  biomarker’s	   sensitivity	  and	  specificity	  of	  detecting	  the	  disease.	   	   If	   the	  test	   is	  perfect,	  all	  patients	  tested	  positive	  would	  have	  the	  disease.	  	  Since	  this	  is	  not	  the	  case	  and	  there	  are	  patients	  that	  test	  positive	  without	  the	  disease,	  the	  discrepancy	  must	  be	  corrected	  for	  the	  TPR	   by	   the	   FPR,	   resulting	   in	   the	   positive	   likelihood	   ratio,	   being	   defined	   as	  (sensitivity)/(1-­‐specificity)	   or	   by	   TPR/FPR	   [6].	   Similarly,	   the	   validity	   of	   a	  negative	  result	  is	  still	  in	  question	  due	  to	  the	  presence	  of	  FN	  patients	  that	  exhibit	  false	   results	   with	   the	   disease	   present.	   The	   negative	   likelihood	   ratio	   is	   then	  defined	   as	   (1-­‐sensitivity)/(specificity)	   or	   FNR/TNR.	   The	   likelihood	   ratios	   have	  two	  advantages:	  1)	  it	  is	  the	  ratio	  of	  sensitivity	  and	  specificity	  alone,	  by	  which	  it	  is	  independent	   of	   population	   settings	   and	   can	   be	   used	   at	   the	   individual	   patient	  level,	   and	   2)	   it	   allows	   a	   quantification	   of	   the	   probability	   of	   disease	   for	   a	  particular	  patient	  [21].	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3.4	  Receiver	  Operating	  Characteristic	  (ROC)	  Curve	  and	  Area	  under	  the	  ROC	  curve	  
(AUC)	  	  ROC	   is	   a	   graphical	   representation,	   which	   uses	   the	   values	   of	   sensitivity	   and	  specificity	  in	  varying	  amount	  of	  possible	  thresholds	  (Note:	  Diagram	  2	  is	  obtained	  under	   some	   certain	   threshold).	   The	   dependence	   between	   sensitivity	   and	  specificity	   induces	  a	  trade-­‐off	  between	  the	  two	  quantities:	  one	  value	   increasing	  while	  the	  other	  decreases	  as	  the	  threshold	  for	  positivity	  is	  moved.	  The	  ROC	  curve	  is	  obtained	  by	  plotting	   sensitivity	   (TPR)	  against	  1–specificity	   (FPR).	   Sensitivity	  and	  specificity	  calculated	  at	  various	  cut-­‐off	  points	  generate	  the	  ROC	  curve,	  which	  is	  the	  main	  model	  used	  to	  assess	  the	  candidate	  biomarker	  correlation	  the	  disease	  phenotype	  [6].	  As	  the	  positivity	  threshold	  is	  varied,	  the	  upper	  left	  hand	  corner	  of	  the	  ROC	  curve	  where	   sensitivity	   is	   1	   and	   specificity	   is	   1.	   Similarly,	   the	   test	   would	   be	  uninformative	   if	   the	   ROC	   curve	   would	   be	   the	   upward	   diagonal	   line.	   If	   the	  distribution	   of	   the	   diseased	   and	   non-­‐diseased	   groups	   are	   not	   similar,	   an	  asymmetrical	   curve	   will	   result	   indicating	   the	   limitation	   of	   this	   quantification	  assessment	   [22].	   Therefore,	   the	   ROC	   curve	   is	   an	   indicator	   of	   the	   candidate’s	  performance,	  since	  it	  shows	  a	  range	  of	  specificity	  of	  the	  candidate.	  Moreover,	  the	  sensitivity	  value	  of	  highly	  specific	  candidate	  is	  more	  important	  than	  that	  of	  low	  specific	  candidate.	  	  The	   area	   under	   the	   curve	   of	   an	   ROC	   curve	   (AUC)	   is	   a	   way	   to	   reduce	   ROC	  performance	   to	   a	   single	   value	   representing	   expected	  performance.	  AUC	   can	  be	  interpreted	  as	  an	  average	  of	  sensitivity	  over	  all	  FPRs	  or	  as	  the	  average	  FPR	  over	  all	  sensitivities	  [23].	  An	  AUC	  value	  of	  0.5	  (50%)	  indicates	  no	  association	  between	  true	  and	  false	  positives,	  and	  a	  value	  of	  1.0	  (100%)	  indicates	  perfect	  association	  [24]	  between	  the	  true	  and	  predicted	  outcome.	  AUC	  is	  a	  systematic	  summary	  over	  sensitivity	  over	  all	  possible	  cases	   (cutoff	  value),	   indicating	  a	  very	  sophisticated	  standard	   to	  measure	   the	   significance	  of	  binary	   classification.	  AUC	  considers	  all	  values	   of	   specificities	   without	   any	   weights	   on	   high	   specificity,	   which	   is	   a	  disadvantage	  of	  AUC.	  	  	  
3.5	  Time-­‐dependent	  ROC	  Curves	  and	  Time-­‐dependent	  AUC	  	  AUC	   has	   become	   the	   "gold	   standard"	   for	   assessing	   performance	   of	  models	   for	  binary	  outcomes.	  Kern	  highlights	  the	  "time"	  factor	  [25,	  26].	  The	  dimensionality	  of	   time	   incorporates	   the	   time-­‐varying	   nature	   of	   the	   clinical	   onset	   time	   of	   the	  disease.	  Hence,	  the	  predictive	  accuracy	  for	  the	  marker	  can	  be	  pronounced	  since	  disease-­‐occurrence	   can	   be	   precisely	  measured	   via	   calculations	   of	   time-­‐specific	  ROC	   curves	   and	   further	   time-­‐specific	   AUC.	   In	   fact	   time-­‐specific	   ROC	   curves	  achieve	   optimal	   accuracy	   in	   predicting	   the	   future	   disease	   status,	   due	   to	   the	  advantage	  of	  capturing	  the	  time-­‐varying	  nature	  of	  markers	  [25,	  27].	  	  
3.6	  Diagnostic	  Odds	  Ratio	  (DOR)	  
	  The	  Diagnostic	  Odds	  Ratio	  (DOR)	  is	  diagnostically	  defined	  as	  the	  positive	  odds	  of	  subjects	  with	  disease	  relative	   to	   the	  odds	  of	  subjects	  without	  disease.	  DOR	  can	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range	   from	   zero	   to	   infinity.	   The	   higher	   values	   of	   DOR	   indicate	   better	   test	  performance	  [15].	  A	  DOR	  of	  less	  than	  one	  indicates	  that	  the	  test	  can	  be	  improved	  simply	  by	   inverting	   the	  outcome	  of	   the	   test.	  A	  DOR	  value	  of	  exactly	  one	  means	  that	   the	   test	   is	   highly	   likely	   to	   predict	   a	   positive	   outcome,	   whatever	   the	   true	  condition.	  The	  definition	  of	  DOR	  can	  be	  written	   in	  a	  variety	  of	  ways,	  mainly	  by	  the	  following	  three:	  	  	  1)	  (TP/FN)/(FP/TN),	  	  	  2)	  a	   ratio	  of	   the	  positive	   likelihood	  ratio	  over	   the	  negative	   likelihood	  ratio,	   i.e.	  (TPR/FPR)/(FNR/TNR),	  	  	  3)	  ((sensitivity)/(1-­‐specificity))/((1-­‐sensitivity)/(specificity)).	  DOR	  depends	  significantly	  on	  the	  sensitivity	  and	  specificity	  of	  a	  test.	  A	  test	  with	  both	   high	   specificity	   and	   sensitivity	   with	   low	   rate	   of	   false	   positives	   and	   false	  negatives	  has	  high	  DOR.	  Maintaining	  same	  sensitivity	  of	  the	  test,	  DOR	  increases	  with	   the	   increase	   of	   the	   test	   specificity.	   For	   example,	   a	   test	   with	   sensitivity	   >	  90%	  and	   specificity	   of	   99%	  has	   a	  DOR	  greater	   than	  500,	  with	   an	   approximate	  95%	   confidence	   interval	   for	   the	   population.	   The	   p-­‐value	   of	   DOR	   is	   <0.05,	  indicating	  studies	  exhibited	  great	  heterogeneity	  [20,	  22,	  28].	  	  	  The	   contingency	   table	   of	   DOR	   is	   generated	   at	   some	   cutoff	   value,	   not	   over	   the	  average	  of	  specificity	  value	  like	  in	  AUC,	  while	  as	  DOR	  can	  be	  shown	  by	  sensitivity	  and	  specificity,	  so	  it	  can	  be	  connected	  to	  AUC	  by	  averaging	  it	  over	  all	  specificities	  by	  changing	  cutoff	  values.	  DOR	  summarizes	  study	  accuracy	   in	  a	  single	  number,	  focusing	   on	   some	   cutoff	   value.	   This	   point	   makes	   DOR	   a	   relatively	   easy	  measurement	  even	  for	  meta-­‐analysis	  (which	  combines	  independent	  studies	  for	  a	  single	  biomarker	  to	  get	  effect	  in	  the	  general	  population).	  This	  is	  possible	  because	  DOR	  can	  be	  combined	  in	  terms	  of	  ratios	  of	  odds	  [28].	  	  	  
3.7	  Issues	  with	  DOR	  
	  DOR	   is	   recently	   increasingly	   used,	   while	   the	   cut-­‐off	   value	   needs	   to	   be	   chosen	  optimally.	   This	   is	   often	   by	   Youden	   index,	   while	   indexing	   a	   cut-­‐off	   value	   to	  maximize	  some	  function	  such	  as	  specificity	  has	  become	  a	  common	  practice.	  For	  example,	  Lotrakul	  et	  al.	  recommended	  the	  cut-­‐off	  value	  at	  9,	  demonstrating	  that	  this	  cut-­‐off	  value	  can	  be	  a	  powerful	  screening	  tool	   for	  patients	  with	  depression	  [29].	  Bohning	  et	  al.	  proposed	  a	  solution	  to	  this	  issue	  by	  plotting	  a	  non-­‐parametric	  estimate	   of	   the	   log-­‐DOR	   against	   the	   cut-­‐off	   value	   [20].	   Another	   procedure	  provides	  a	  prospective	  statistical	  test	  for	  the	  hypotheses,	  to	  determine	  if	  the	  test	  treatment	  is	  beneficial	  for	  the	  entire	  patient	  population	  or	  only	  for	  that	  subgroup	  defined	   by	   the	   biomarker	   [30].	   In	   other	  words,	   it	   provides	   an	   estimate	   of	   the	  optimal	   biomarker	   cut-­‐off	   point.	   Glas	   et	   al.	   suggested	   the	   DOR	   as	   a	   single	  indicator	  of	  test	  performance	  to	  facilitate	  the	  formal	  meta-­‐analysis	  of	  studies	  on	  diagnostic	   test	   performance	   [31],	   while	   still	   the	   precision	   of	   DOR	   has	   to	   be	  optimized	   by	   choosing	   the	   cut-­‐off	   value	   [32].	   We	   can	   thus	   say	   that	   it	   is	   still	  unclear	   on	   how	   to	   determine	   the	   cutoff	   value	   for	  DOR.	   Fischer	   and	   colleagues	  developed	  a	  recommended	  guide	  to	  enhance	  the	  appraisal	  of	  diagnostic	  tests	  to	  combine	  several	  measures	  of	   test	  accuracy,	  such	  as	  sensitivity,	  specificity,	  ROC,	  LR	  and	  DOR	   [33].	  Also	  Pepe	  et	   al.	   showed	   the	   relation	  between	  DOR	  and	  AUC,	  and	  show	  that	  an	  OR	  as	  large	  as	  3.0	  may	  have	  little	  impact	  on	  AUC	  [5,	  34,	  35].	  In	  conclusion,	   despite	   the	   increased	   use	   of	   DOR	   in	   the	   medical	   literature,	   it	   has	  
	   9	  
many	   flaws	   in	   its	  measurements	   and	  might	   still	   remain	   poorly	   understood	   by	  clinicians	  [28].	  	  
3.8	  Latest	  Measures	  	  Along	   with	   the	   recent	   trend	   on	   computational	   methods	   for	   evaluating	  biomarkers,	  we	  here	   raise	   new	  and	   rather	   under-­‐developing	  measures	   on	   two	  cases:	   1)	   two	   or	   more	   studies	   for	   a	   single	   biomarker,	   and	   2)	   one	   study	   for	  multiple	  biomarkers.	  	  Now	   various	   studies	   for	   a	   single	   biomarker	   can	   be	   generated	   [8,	   15].	   For	  example,	  even	  by	  the	  same	  research	  group,	  studies	  can	  be	  repeated	  at	  a	  certain	  time	   interval.	   We	   can	   analyze	   them	   to	   get	   its	   widened	   effect	   in	   the	   general	  population.	   Two	   (or	   more)	   studies	   can	   be	   summarized	   into	   so-­‐called	  reclassification	  tables,	  from	  which	  sensitivity	  and	  specificity	  of	  each	  study	  can	  be	  derived.	  The	  reclassification	  table-­‐based	  approaches	  have	  recently	  been	  gaining	  popularity,	  where	  a	  typical	  measure	  is	  "net	  reclassification	  improvement	  (NRI)"	  (which	   is	   slightly	   modified	   into	   IDI	   (integrated	   discrimination	   improvement)	  later)	  [26,	  35].	  NRI	  or	  IDI	  is	  a	  function,	  which	  sums	  sensitivity	  and	  specificity	  of	  one	  study.	  For	  example,	  for	  two	  diagnostic	  tests,	  NRI	  is	  defined	  as	  the	  difference	  between	  two	  tests,	  each	  being	  the	  sum	  of	  specificity	  and	  sensitivity:	  NRI	  =	  (Sensitivity	  +	  Specificity)second	  test	  –	  (Sensitivity	  +	  Specificity)first	  test	  NRI	  sums	  two	  rates	  (sensitivity	  and	  specificity)	  rather	  than	  a	  weighted	  average	  of	   the	   two	  rates	  based	  on	  the	  ratio	  of	  patients	  with	  disease	   to	  without	  disease.	  The	   sum	   of	   sensitivity	   and	   specificity	   is	   equivalent	   to	   Youden	   index,	   meaning	  that	  NRI	  compares	  the	  performance	  of	  two	  tests.	  Two	  performance	  results	  might	  be	   similar	   even	   if	   the	   performance	   is	   low.	   This	   implies	   that	   NRI	   checks	   the	  stability	  of	  two	  studies	  rather	  than	  examining	  the	  significance	  of	  the	  biomarker	  itself.	  Thus	  NRI	  would	  be	  more	  appropriate	  for	  evaluating	  the	  similarity	  of	  two	  different	  models	  rather	  than	  evaluating	  a	  single	  biomarker	  by	  two	  studies,	  where	  one	  model	  means	  a	  certain	  variable	  set	  or	  a	  particular	  condition	  such	  as	  a	  time	  point.	   So	   one	  possible	   case	   is	   that	   one	  model	   has	   a	   set	   of	   biomarkers	   and	  one	  different	  biomarker	  is	  added	  to	  this	  set	  to	  generate	  the	  other	  model.	  	  The	   combination	   of	   multiple	   biomarkers	   would	   be	   one	   direction	   to	   achieve	  higher	  discriminative	  performance.	  For	  example,	  OVA1,	  a	  FDA	  approved	  test	  for	  pre-­‐surgical	   evaluation	   of	   a	   woman's	   ovarian	   mass	   for	   cancer,	   examines	   five	  biomarkers:	  transthyretin,	  apolipoprotein,	  A-­‐1,	  2-­‐microglobulin,	  transferrin,	  and	  CA-­‐125	   [36].	   OVA1	   demonstrated	   90%	   sensitivity	   for	   ovarian	   cancers	   stages	   I	  compared	  with	  61%	  for	  CA-­‐125	  [37].	  Surprisingly,	  however,	   the	  specificity	  and	  positive	  predictive	  value	  of	  OVA1	  with	  physician	  assessment	  was	  worse	  than	  CA-­‐125	   alone	   [38,	   39].	   One	   possible	   explanation	   for	   this	   result	   is	   the	  menopausal	  status	   that	   skews	   the	   results	   for	   this	   multivariate	   index	   assay.	   After	   OVA1,	  researchers	  have	  developed	  computational	   tools	   for	  diagnosis	  procedures	  with	  multiple	  biomarkers.	  ROMA	  (Risk	  of	  Ovarian	  Malignancy	  Algorithm)	  focuses	  on	  two	  biomarkers	   for	  ovarian	  cancer:	  HE4	  and	  CA-­‐125	  [38,	  39].	  ROMA	  calculates	  “predictive	   index”	  (the	   final	  score	  given	  by	  the	   logit	  of	   the	  predictive	   index)	  by	  linear	  regression	  over	  the	  serum	  concentration	  of	  two	  biomarkers.	  An	  important	  point	   of	   ROMA	   is	   that	   those	   linear	   equations	   are	   changed	   by	   the	   patient's	  
	   10	  
menopausal	  status	  at	  the	  time	  of	  testing,	  to	  solve	  the	  low	  specificity	  problem	  of	  OVA1	   [38].	   ROMA	   is	   currently	   promoted	   for	   two	  major	   reasons,	   compared	   to	  OVA1.	  First,	  ROMA	  reports	  a	  higher	  specificity	   [38,	  39].	  Second,	  ROMA	   is	  more	  cost-­‐effective,	  because	  it	  has	  less	  markers.	  	  
 
4.	  Current	  Biomarkers	  	  Table	  1	  provides	  a	  comprehensive	  comparison	  of	  current	  potential	  and	  approved	  biomarkers,	   including	   26	   biomolecules,	   2	   metabolic	   biomarkers	   and	   4	   cell	  biomarkers.	   A	   unique	   feature	   of	   this	   table	   is	   positive	   and	   negative	   predictive	  values	   and	   DOR,	   which	   are	   extracted	   from	   corresponding	   references	   and	  attached	  to	  all	  biomarkers.	  Furthermore,	  one	  marker	  can	  be	  used	  for	  evaluating	  more	  than	  one	  cancer	  type.	  For	  example,	  heat	  shock	  proteins	  (HSPs)	  are	  used	  for	  five	   types:	   gastric,	   prostate,	   osteosarcoma,	   uterine	   and	   bladder,	   meaning	   five	  DOR	  values	   for	   all	   five	   types	   in	  HSPs.	   The	  DOR	   in	   this	   table	   takes	   a	   very	  wide	  range	  of	  values,	  while	  all	  values	  are	  reasonably	  larger	  than	  1.0,	  except	  only	  seven	  cases.	  The	   largest	  DOR	  value	   is	  218.5	   for	  breast	  cancer	  by	  cfDNA,	  and	   the	  next	  largest	  is	  104.816	  for	  colorectal	  cancer	  by	  DR-­‐70.	  Again	  we	  stress	  that	  this	  table	  is	  a	  thorough	  summary	  on	  current	  all	  possible	  cancer	  biomarkers.	  	  One	   important	   issue	   of	   cancer	   biomarkers	   is	   to	   identify	   cancer-­‐specific	  biomarkers,	   by	   which	   the	   cancer	   type	   of	   a	   patient	   would	   be	   detected	   more	  accurately.	  For	  example,	  DOR	  of	   cfDNA	   in	  a	  breast	  cancer	  patient	   is	  218.5.	  The	  odds	  of	  having	  cfDNA	  due	  to	  a	  metastatic	  carcinoma	  is	  known	  as	  2.29	  [40],	  and	  even	   the	   odds	   ratio	   of	   having	   cfDNA	   in	   the	   blood	   from	   breast	   cancer	   can	   be	  218.5/2.29=95.41.	  This	  will	   give	   researchers	   the	  conclusion	   that	   cfDNA	  will	  be	  95	  times	  more	  likely	  to	  be	  present	  in	  the	  blood	  of	  a	  breast	  cancer	  patient	  than	  in	  a	  patient	  with	   another	   type	  of	   carcinoma,	  meaning	   that	   cfDNA	  can	  be	   a	  breast	  cancer-­‐specific	  biomarker.	  On	   the	  other	  hand,	  CA19-­‐9	  can	  be	  detected	   in	   three	  cancers:	   pancreatic,	   ovarian	   and	   bladder,	  where	   three	   DOR	   values	   are	   15.637,	  23.7	  and	  20.16,	  respectively,	  all	  being	  relatively	  high	  and	  similar.	  HSPs	  also	  has	  relatively	   similar	   values	   for	   five	   types,	   particularly	   two	   tumors,	   i.e.	  osteocarcinoma	  and	  prostate,	  having	   the	   same	  value,	  2.25.	   In	   these	   cases,	  DOR	  would	   not	   be	   an	   appropriate	   measure	   to	   identify	   a	   cancer-­‐type	   specific	  biomarker.	  	  	  	  
5.	  Discussion	  	  As	   explained	   in	   Section	   3.8,	   OVA1	   (approved	   in	   2009)	   for	   ovarian	   carcinoma	  with	   five	   biomarkers	   including	   CA-­‐125	   had	   to	   show	   weaker	   performance	   in	  terms	  of	  specificity	  and	  positive	  predictive	  value	  than	  CA-­‐125	  alone	  (approved	  in	  1997).	   This	   implies	   the	   need	   of	   improved	   statistical	   quantification	  methods	   to	  decrease	   the	   lack	  of	  specificity	   in	   the	  current	   instrumentation	  methods	   for	   low	  abundance	   proteins.	   This	   point	   brought	   a	   mentality	   shift	   focusing	   on	   a	   more	  robust	   statistical	   predictive	   tool,	   resulting	   in	   the	   Risk	   of	   Ovarian	   Malignancy	  Algorithm	   (ROMA),	   more	   generally	   a	   predictive	   model,	   i.e.	   logistic	   regression	  over	  two	  variables	  [38].	  	  	  The	  development	  of	  ROMA	  is,	  on	  evaluating	  biomarkers,	  solving	  many	  important	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problems,	  which	  in	  general	  could	  not	  be	  overcome	  by	  previous	  methods.	  These	  problems	   would	   be	   summarized	   into	   three	   issues:	   1)	   interpretation	   issue,	   2)	  statistical	  error,	  and	  3)	  technical	  (experimental)	  error.	  	  1)	   Interpretation	   issue:	   previous	   measures	   like	   DOR	   have	   rather	   simple	  definitions	  and	  can	  be	  easily	  computed,	  while	   it	  might	  be	  hard	   for	  clinicians	   to	  understand	  them	  accurately	  and	  use	  them	  properly	  for	  diagnosis	  and	  prognosis	  purposes.	  On	   the	  other	  hand,	  ROMA,	   a	  predictive	  model,	   gives	   a	   score	  or	   a	   so-­‐called	   risk,	   i.e.	   the	   probability	   that	   a	   patient	   will	   be	   with	   the	   disease	   (in	   the	  future).	   The	   score	   can	   be	   used	   for	   diagnosis	   directly,	  meaning	   that	   though	   the	  model	  behind	  the	  measure	  might	  be	  still	  a	  blackbox	  for	  clinicians,	  the	  model	  can	  show	  the	  score	  for	  any	  disease	  category	  like	  stage	  I	  to	  V	  of	  cancer	  progress	  more	  clearly.	  This	  would	  be	  more	  accepted	  by	  researchers/practitioners.	  	  2)	  Statistical	  errors:	  one	  study	  has	  an	  unavoidable	  limitation	  on	  its	  sample	  size,	  sometimes	  causing	  a	  significant	  bias.	  To	  overcome	  this	  issue,	  a	  popular	  approach	  is	   meta-­‐analysis,	   where	   independent	   studies	   are	   gathered	   and	   their	   statistical	  features,	  such	  as	  DOR,	  can	  be	  combined.	  Meta-­‐analysis	  is	  a	  sophisticated	  manner	  to	   compensate	   many	   issues	   of	   a	   single	   study,	   particularly	   bias,	   while	   it	   is	  impossible	   to	   remove	   these	   issues	   completely,	   because	   usually	   meta-­‐analysis	  uses	   only	   the	   statistics	   derived	   from	   the	   original	   studies	   and	   these	   statistics	  eventually	   have	   to	   keep	   the	   original	   issue.	   On	   the	   other	   hand,	   ROMA	   uses	   a	  predictive	   model,	   in	   which	   parameters,	   such	   as	   coefficients	   of	   the	   linear	  equations,	   should	   be	   estimated	   from	   the	   original	   instances,	   where	   each	   single	  assay	  can	  be	  one	   instance.	  This	   implies	   that	  a	  predictive	  model	   is	  more	  robust,	  being	   rather	   released	   from	   the	  bias	  generated	   in	  each	  original	   study,	  by	  which	  the	  predictive	  model	  makes	  meta-­‐study	  easier	  than	  ever.	  	  3)	  Technical	   errors:	  The	  current	   technological	   innovation	  has	  not	  achieved	   the	  sufficient	  sensitivity	  to	  properly	  identify	  the	  low	  abundance	  proteins.	   	  Until	  the	  instrumentation	   is	   drastically	   improved,	   highly	   predictive	   statistical	  quantification	   methods	   are	   needed	   to	   decrease	   the	   lack	   of	   specificity	   in	   the	  current	   instrumentation	   methods.	   One	   possible	   solution	   is	   definitely	   meta-­‐analysis,	  and	  as	  explained	  above,	  predictive	  models,	  such	  as	  ROMA,	  would	  be	  a	  further	  solution	  for	  this	  problem.	  	  Overall	  developing	  predictive	  models	  would	  be	  a	  highly	  promising	  direction	   to	  achieve	  higher	  diagnostic,	  prognostic	  and	  predictive	  performance	  for	  evaluating	  biomarkers.	   ROMA	   uses	   logistic	   regression,	   which	   is	   a	   widely	   used	   basic	   and	  powerful	  predictive	  model.	  Higher	  performance	  models	  than	  logistic	  regression	  are	  already	  developed	  in	  machine	  learning	  and	  are	  currently	  well-­‐used	  in	  many	  applications.	  For	  example,	  regression	  trees	  and	  support	  vector	  regression	  were	  utilized	   for	   validating	   biomarkers	   already	   [41].	   Further	   high-­‐performance	  predictive	  methods	  might	  be	  used	  in	  the	  future,	  and	  might	  change	  the	  quality	  of	  cancer	   biomarker	   evaluation.	   Another	   possible	   direction	   would	   combine	  predictive	  models	  with	   previous	  measures	   like	  DOR.	   For	   example,	   ROMA	  with	  DOR	  might	   be	   a	   powerful	   technique	   that	   statistics	   can	   play	   to	   compensate	   the	  lack	  of	  precision	  and	  accuracy	  used	  to	  validate	  the	  candidate	  biomarker.	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Tables	  	  
Table	  1	  	  A	  comprehensive	  list	  of	  currently	  popular	  or	  approved	  biomarkers.	  	  The	   following	   table	   details	   the	   characteristics,	   applications	   and	   a	   quantitative	  measure	  of	  its	  quality	  as	  a	  clinical	  diagnostic	  tool	  in	  its	  respective	  cancer	  [3,	  36,	  44-­‐109]	  	  
Figure	  Legends	  &	  Figures	  	  
	  
Diagram	  1	  	  EDRN:	  Phases	  of	  Biomarker	  Development.	  The	   large	   number	   of	   biomolecules	   that	   are	   initially	   considered	   as	   potential	  candidates	  pass	   through	   the	  other	   stages	   (Phase	   II-­‐V)	   to	  validate	   its	   specificity	  and	   sensitivity	   in	   diagnosis,	   prognosis,	   and	   for	   treatment	   prediction.	   The	   long,	  costly	  and	  stringent	  road	  through	  the	  five-­‐phase	  process	  filters	  the	  candidates	  to	  the	  ‘certain	  few’	  that	  are	  FDA	  approved	  [5,	  7].	  	  	  	  	  	  	  	  	  	  	  
Diagram	  2	  	  Biomarker	   Performance	   Characteristics:	   Quantification	   Assessment	   of	  Biomarker.	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This	   contingency	   table	   distinguishes	   the	   population	   pool	   into	   the	   various	  subgroups	  (TP,	  FP,	  FN,	  TN),	  depending	  on	   the	  absence	  and	   the	  presence	  of	   the	  biomarker.	  This	  subsequently	  quantifies	  the	  sensitivity	  and	  the	  specificity	  of	  the	  biomarker	  correlated	  to	  the	  disease.	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